PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich’s ataxia, with the FDA stating that substantial evidence of efficacy was not demonstrated and that an additional adequate and well-controlled study would be needed, RBC Capital tells investors in a research note. The firm believes this was generally expected and already baked into the stock, and thinks the focus will hone in on the Sephience launch. RBC Capital, which has an Outperform rating and $63 price target on the stock, would buy shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback
- PTC Therapeutics price target lowered to $50 from $56 at TD Cowen
- PTC Therapeutics: Hold Rating Amid Regulatory Setbacks and Sephience Growth Potential
- PTC Therapeutics Receives FDA Complete Response Letter
- PTC Therapeutics receives Complete Response Letter for vatiquinone NDA